$500 savings expire in:
- 00Days
- 00Hrs
- 00Mins
- 00Secs
Day 1 - SGT / Singapore
As APAC rapidly strengthens its position within the global healthcare ecosystem, biotech and medtech companies across the region are increasingly focused on scaling innovation, securing strategic partnerships, and expanding internationally. This opening keynote explores how investment, cross-border collaboration, AI, digital health, and commercial strategy are reshaping healthcare innovation across Asia-Pacific, and what will define the next generation of globally competitive healthcare companies.
- Which APAC markets are emerging as the strongest global innovation hubs?
- How are biotech, medtech, AI, and digital health converging to reshape healthcare delivery, investment strategy, and competitive positioning?
- What strategies are helping APAC healthcare companies scale internationally and compete globally?
- Are biotech companies increasingly being valued for their data assets, AI capabilities, and platform intelligence as much as their therapeutic pipelines?
- Helen Chen - Global Sector Co-Head, Healthcare & Life Sciences, L.E.K. Consulting
- Sharon Chan - VP JLABS, APAC, Johnson & Johnson
- Irene Cheong - Assistant Chief Executive, Innovation & Research, A*Star
- Kevin Ding - Vice President, Goldman Sachs
The APAC partnering landscape continues to evolve rapidly as global pharma expands its search for innovation beyond traditional markets. This session explores where deal activity is accelerating across Asia, which markets are attracting strategic attention, and how regional biotech companies are positioning themselves within an increasingly competitive global environment.
- Which APAC markets are generating the strongest partnering momentum?
- What types of assets and technologies are attracting the greatest global interest?
- How are regional biotech companies differentiating themselves in today’s market?
- How are tightening capital markets, LP pressure, and changing crossover investor activity reshaping APAC biotech funding and partnering strategies?
- Irene Hong - Founding Partner, CEC Capital
- Tom Wu - Head of Ventures, Asia Pacific, AbbVie
- Martin Taylor - Principal, F-Prime Capital
As APAC biotech companies mature, many are reassessing traditional licensing strategies in favour of co-development models, regional rights retention, and long-term value creation. At the same time, global pharma is increasingly looking to Asia not only for assets, but also for discovery, translational research, and development capabilities. How are global pharma companies evolving their Asia sourcing and partnership strategies beyond traditional licensing?
- What does the next generation of pharma-biotech collaboration in Asia actually look like?
- Where are companies still struggling to align on control, value creation, and long-term partnership strategy?
- How are APAC biotech companies balancing short-term capital needs with longer-term strategic growth ambitions?
Medtech in the Asia Pacific is at a pivotal moment, with growing demand for advanced healthcare solutions and increasing investment in innovation. This panel will delve into the unique opportunities and challenges facing Medtech companies in the region and outline actionable steps for sustainable growth.
- Emerging trends and opportunities in the Asia Pacific Medtech landscape
Navigating regulatory hurdles and market-specific challenges
Building a roadmap for innovation, collaboration, and commercialization
- Colin Tan - Investment Director, Coronet Ventures
- Shelby Zhang - Executive Director, Vertex Growth Fund
Strategic partnerships with Tier 1 medtech and pharma companies can be game-changing for startups, providing access to resources, expertise, and global networks. This session will explore how startups can effectively engage with industry giants to drive growth and innovation.
Identifying and approaching Tier 1 medtech and pharma companies
Structuring partnerships for mutual benefit and long-term success
Leveraging partnerships to accelerate product development and market entry
As partnership models become increasingly sophisticated across APAC, companies are rethinking how deals are structured, evaluated, and executed across the biotech lifecycle. This practical discussion explores how pharma, biotech, and investors approach valuation, diligence, deal structures, and long-term collaboration strategy in today’s market.
- How do companies determine whether an asset is best suited for licensing, co-development, or strategic collaboration?
- Understanding how valuation expectations shift across discovery, clinical development, and commercialization stages.
- What recent deals reveal about the factors accelerating (or derailing) partnership discussions and negotiations?
- Why is integration planning becoming increasingly important to long-term partnership success?
- Frank Grams - Chief Business Development & Licensing Officer, Partex NV
APAC biotech companies are pursuing global ambitions earlier than ever before, but scaling internationally brings significant operational, regulatory, and commercial challenges. This session explores how companies are balancing regional strength with global competitiveness while navigating partnerships, expansion strategies, and increasingly selective capital markets.
- How are regulatory strategy and market access planning influencing global expansion decisions earlier in the company lifecycle?
- At what stage should companies begin building global strategies, and what are the biggest challenges when scaling beyond APAC?
- How important are strategic partnerships in accelerating international growth?
Family offices are increasingly investing in medtech and digital health startups, offering patient capital and strategic support. This panel will provide insights into how startups can attract family office investment and build lasting relationships with these unique investors.
Understanding the investment priorities of family offices
Crafting compelling pitches tailored to family office investors
Building trust and long-term relationships with family offices
Regulatory harmonization is critical for medtech companies seeking to scale across the Asia Pacific region. This panel will examine the feasibility, timelines, and progress of regulatory alignment, and its impact on innovation and market access.
Current state of medtech regulations in the Asia Pacific
Challenges and opportunities in regulatory harmonization
Practical steps for navigating regulatory frameworks across the region
- Rex Tan - Chief Technology Officer, Aevice Health
Back for another year, Startup Spotlight showcases a curated selection of emerging biotech innovators from across APAC. Designed to connect early-stage companies with investors, pharma, and strategic partners, the session highlights breakthrough science, platform technologies, and companies shaping the next generation of healthcare innovation across the region.